What is it about?
Review on epidemiological, microbiological, pharmacological, and clinical data on intravenous fosfomycin therapy against Pseudomonas.
Featured Image
Photo by CDC on Unsplash
Read the Original
This page is a summary of: Intravenous Fosfomycin for Systemic Multidrug-Resistant Pseudomonas aeruginosa Infections, Antibiotics, November 2023, MDPI AG,
DOI: 10.3390/antibiotics12121653.
You can read the full text:
Contributors
The following have contributed to this page
